Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | APAF1 | O14727 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HK1 | P19367 | 1/20 | 0.42 |
| ▸ | GALK1 | P51570 | 1/20 | 0.42 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.34 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.34 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | AHR | P35869 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17460456 | 0.73 | MEN1 (0.42) | IDO1MEN1KMT2AALDH1A1MAPT | |
| Isatin SCHEMBL31087266 | 0.73 | MEN1 (0.59) | MEN1KMT2AALDH1A1MAPTAPAF1 | |
| Isatin SCHEMBL28614049 | 0.73 | MEN1 (0.59) | MEN1KMT2AALDH1A1MAPTAPAF1 | |
| SCHEMBL5971254 | 0.70 | IDO1 (1.00) | IDO1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL1635009 | 0.65 | NOS3 (0.39) | MEN1KMT2AALDH1A1MAPTL3MBTL1 | |
| SCHEMBL11205230 | 0.65 | KDM4E (0.53) | IDO1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL4515365 | 0.64 | IDO1 (0.54) | IDO1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL1404502 | 0.62 | MAPT (0.36) | IDO1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL5712107 | 0.61 | S100A4 (0.58) | IDO1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL29481018 | 0.61 | S100A4 (0.58) | IDO1MEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107151225-B | 2-hydroxyindole derivatives, preparation method and application thereof | 贵州大学 | 2020-05-08 | — | — | CN | disclosed |
| US-9403789-B2 | Benzofuran-containing amino acid inhibitors of cytochrome P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150284352-A1 | METHODS FOR INHIBITING DRUG DEGRADATION | SEQUOIA PHARMACEUTICALS INC (US) | 2015-10-08 | — | — | US | disclosed |
| US-8952056-B2 | Methods for inhibiting drug degradation | SEQUOIA PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8703700-B2 | Bimacrocylic HCV NS3 protease inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8673970-B2 | HIV protease inhibitor and cytochrome p450 inhibitor combinations | SEQUOIA PHARMACEUTICALS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| EP-2432318-A1 | BIMACROCYCLIC HCV NS3 PROTEASE INHIBITORS | Sequoia Pharmaceuticals, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2422780-A1 | Resistance-repellent retroviral protease inhibitors | Sequoia Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| EP-2422781-A1 | Resistance-repellent retroviral protease inhibitors | Sequoia Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| US-7378441-B2 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2008-05-27 | — | — | US | disclosed |
| WO-2005087728-A9 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS INC (US) | 2007-04-26 | — | — | WO | disclosed |
| CN-1953964-A | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2007-04-25 | — | — | CN | disclosed |
| EP-1750696-A2 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2007-02-14 | — | — | EP | disclosed |
| EP-1732891-A1 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060258627-A1 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2006-11-16 | — | — | US | disclosed |
| US-20050267074-A1 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2005-12-01 | — | — | US | disclosed |
| WO-2005110428-A2 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050209301-A1 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2005-09-22 | — | — | US | disclosed |
| WO-2005087728-A1 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267074-A1 | Resistance-repellent retroviral protease inhibitors | SERPINB1, MMP7, MME | IDO1 1811/4885MEN1 3832/4885KMT2A 2140/4885 |
| US-20060258627-A1 | Resistance-repellent retroviral protease inhibitors | SERPINB1, MMP7, MME | IDO1 1811/4885MEN1 3832/4885KMT2A 2140/4885 |
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | HAVCR2, CTRC, CTSC | IDO1 1960/4885MEN1 4791/4885KMT2A 4266/4885 |
| US-20150284352-A1 | METHODS FOR INHIBITING DRUG DEGRADATION | CYP2E1, CYP3A43, CYP3A5 | IDO1 767/4885MEN1 4748/4885KMT2A 3066/4885 |
| US-20050209301-A1 | Resistance-repellent retroviral protease inhibitors | SERPINB1, MMP7, MME | IDO1 1811/4885MEN1 3832/4885KMT2A 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.